BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program - 2Gov’t approves millions for border cities in North under Hezbollah fire
- 3Spain breaks jobs record with 22 million Social Security contributors
- 4Cases of norovirus are on the rise just in time for the holiday season
- 5Incredible Travel Objections for Craftsmanship Darlings to Visit
- Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Study casts doubt on potential for life on Jupiter's moon Europa
- Floods, Landslides Triggered By Heavy Rain In Afghanistan Leave 77 Dead In 10 days, Authorities Say
- 10 Energizing Vocations in the Innovation Business
- Why most Jewish Israelis back the death penalty for terrorists
- What to expect from the planets in 2026 — key dates and sky events
- IDF strikes terror infrastructure across Iran, attack reported on Kashan airport
- Manual for Big name Work out schedules
- America's Confided in Cooler in 2024
